EBV Infection Clinical Trial
Official title:
Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection.
Worldwide, 95% of adults are infected with Epstein-Barr Virus (EBV). These infections may cause different diseases. In most cases, EBV infection is asymptomatic because of a highly effective host immune response. Some individuals develop infectious mononucleosis (a self-limiting lymphoproliferative disorder in adolescents and young adults that is considered to be the primary infection), while others develop chronic fatigue syndrome, EBV-associated lymphoid, or epithelial malignancies. Today, there is no available treatment to treat and destroy EBV. The treatment is essentially symptomatic (treatment of the symptoms and not of the virus itself) with analgesics for pain for example. The studied drugs are 2LEBV® and 2LXFS®, from Labo'Life company, and the treatment schema is the same for the two drugs: it consists in taking the content of one capsule per day, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be of 6 months of continuous intake of the content of 1 capsule/day. The aim of this study is to provide additional information on effectiveness on the 2LEBV® and 2LXFS®in the treatment of EBV chronic and acute infections, and in particular to demonstrate their effectiveness versus placebo in the reduction of asthenia and other symptoms in EBV infection.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04084626 -
PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV
|
Phase 3 | |
| Completed |
NCT00711035 -
Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06075927 -
Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05039580 -
Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line Therapy
|
Phase 4 | |
| Recruiting |
NCT04782674 -
Study on the Application of Saliva EBV-DNA Detection in EBV Infection Related Diseases
|
||
| Active, not recruiting |
NCT03475212 -
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03159364 -
Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04690036 -
PD-1 Antibody for Reactive EBV After BMT
|
Early Phase 1 | |
| Recruiting |
NCT03491605 -
Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection
|
||
| Recruiting |
NCT04189835 -
EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients
|
||
| Recruiting |
NCT05682703 -
A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Nasopharyngeal Carcinoma.
|
||
| Completed |
NCT05604378 -
Relationship of EBV-positive Gastric Cancer and Multiple Genes Associated With Gastric Carcinogenesis
|
||
| Recruiting |
NCT04832607 -
Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections
|
Phase 3 | |
| Recruiting |
NCT06135922 -
Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection
|
Phase 1 | |
| No longer available |
NCT01945619 -
Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
|
N/A |